All In Biotech

Free tool

FAERS Monitor: Lotemax Sm

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208219 or its brand name (Lotemax Sm, Loteprednol Etabonate). Reports on generic versions are filed under their own applications.

Reports

944

Serious

290

31% of reports

Hospitalization

82

Death reported

15

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • eye pain163
  • eye irritation116
  • vision blurred74
  • product use in unapproved indication72
  • off label use67
  • drug ineffective60
  • headache56
  • ocular hyperaemia53
  • photophobia47
  • product dose omission issue45
  • fatigue40
  • inappropriate schedule of product administration40
  • eye swelling39
  • pruritus38
  • lacrimation increased35

Reports by year received

View as table
YearReports
20043
20053
20081
20092
20104
20112
20123
20135
20143
20158
20165
20176
201811
201950
202073
202188
2022132
2023133
2024157
2025135
2026120

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,215 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
eye painSignal16364.656.110,133
photophobiaSignal4755.842.22,471
eye irritationSignal11645.037.94,949
lacrimation increasedSignal3525.818.7811
ocular hyperaemiaSignal5324.919.21,194
eye swellingSignal3923.417.2814
vision blurredSignal7412.09.7741
product use in unapproved indicationSignal726.55.2332
inappropriate schedule of product administrationSignal404.93.7123
product dose omission issueSignal453.42.675
pruritusSignal382.21.624
headache562.01.527
off label use671.71.420
fatigue401.10.81
drug ineffective601.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.